CD8A and neoplasm: Somewhat surprisingly, tumor antigen loss variants (ALV) were also observed following IP administered MRB-OVA boost, where the OVA-specific CD8+ T cell response was considerably lower than by IV/IP delivery, suggesting the anti-tumor T cell response following IV/IP boosting was well beyond the threshold required to eliminate all OVA-expressing tumor cells in the day 5 therapeutic model.